Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights

— 1 min read

Pomerantz LLP has announced the filing of a class action lawsuit against Alto Neuroscience, Inc. and certain officers in the United States District Court for the Northern District of California. The lawsuit is on behalf of a class of investors who purchased or acquired Alto common stock in connection with the Company's initial public offering on February 2, 2024, or purchased or acquired Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Key Takeaways:

  • The class action lawsuit alleges that Alto's product pipeline, including ALTO-100, was misrepresented in the Offering Documents and that the Company's clinical, regulatory, and commercial prospects were overstated.
  • The lawsuit claims that ALTO-100's clinical trial results were less effective in treating major depressive disorder (MDD) than Defendants had led investors to believe.
  • Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024, after the Company announced topline results from the Phase 2b trial evaluating ALTO-100.
  • Pomerantz LLP has recovered billions of dollars in damages awards on behalf of class members in similar cases.
  • The lawsuit is open to all persons and entities that purchased or acquired Alto securities during the Class Period.
  • The deadline to ask the Court to appoint Lead Plaintiff is September 19, 2025.

Statistics:

  • 8,040,000 shares of Alto common stock were issued in the Company's initial public offering on February 2, 2024, at an Offering price of $16.00 per share.
  • The Offering generated proceeds of $119,635,200 to Alto after applicable underwriting discounts and commissions, and before expenses.
  • Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • Jeffries cut its price target for Alto to $17 from $33 in response to the Company's announcement.
  • Alto's common stock continues to trade below the $16.00 per share Offering price.

Sources:

  • Pomerantz LLP
  • United States District Court for the Northern District of California
  • Securities and Exchange Commission (SEC)
  • New York Stock Exchange
  • Jeffries
  • Pomerantz LLP website

Read more